Journal
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 39, Issue 3, Pages 567-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2013.02.001
Keywords
Osteoarthritis; Imaging; Radiography; MR imaging; Ultrasonography; CT; PET
Categories
Funding
- Genzyme
- Stryker
- Merck Serono
- Novartis
- Astra Zeneca
- General Electric Healthcare
- National Institutes of Health
Ask authors/readers for more resources
Slowing of radiographic joint space narrowing represents the only recommended imaging-based outcome measure to assess structural disease progression in osteoarthritis (OA) clinical trials. There are no effective disease-modifying OA drugs. The ability of magnetic resonance (MR) to image structures within the knee and to visualize cartilage morphology and composition gives MR imaging a critical role in understanding the natural history of the disease and in the search for therapies. In this article, the roles and limitations of conventional radiography and MR imaging, focusing on knee OA, and the use of other modalities in clinical practice and OA research are described.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available